Vectura initiates legal proceedings against GSK
Vectura announced it has received formal notification from GlaxoSmithKline that GSK does not wish to exercise the option to take a license to any additional patents under the patent licence and option agreement with Vectura dated 5th August 2010 for GSK’s Ellipta® products. July 27, 2016